Informação da revista
Vol. 38. Núm. 3.
Páginas 225.e1-225.e5 (março 2019)
Baixar PDF
Mais opções do artigo
Vol. 38. Núm. 3.
Páginas 225.e1-225.e5 (março 2019)
Case report
Open Access
Three-vessel myocardial bridging: A possible cause of myocardial stunning
Bridging miocárdico dos três territórios coronários – Uma causa possível de atordoamento miocárdico
Ana Rita Almeidaa,
Autor para correspondência

Corresponding author.
, Ana Rita Pereiraa, Gonçalo Morgadoa, Maria José Loureiroa, Filipa Ferreiraa, Inês Cruza, Luís Rocha Lopesb,c,d, Hélder Pereiraa
a Cardiology Department, Hospital Garcia de Orta, Almada, Portugal
b Barts Heart Centre, Barts Health NHS Trust, London, England, United Kingdom
c Institute of Cardiovascular Science, University College London, London, England, United Kingdom
d Centro Cardiovascular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
Este item recebeu

Under a Creative Commons license
Informação do artigo
Texto Completo
Baixar PDF
Figuras (4)
Mostrar maisMostrar menos

The authors report a rare clinical case of myocardial bridging of the three major coronary arteries, which manifested in an unusual way with severe biventricular dysfunction in the context of tachycardia. For the diagnosis, the authors relied on non-invasive multimodality cardiac imaging, including cardiac magnetic resonance, computed tomography angiography and myocardial perfusion scintigraphy. The implementation of targeted medical and neurohormonal therapy resulted in the recovery of ventricular function and clinical improvement.

Myocardial bridging
Myocardial stunning
Heart failure

Os autores descrevem um caso clínico raro de bridging miocárdico dos três territórios coronários, que se apresentou de forma invulgar com disfunção biventricular grave em contexto de taquicardia. Para o diagnóstico os autores basearam-se em exames de imagem cardíaca não invasivos, como a ressonância magnética cardíaca, a angiografia tomográfica computorizada e a cintigrafia de perfusão miocárdica. A instituição de terapêutica médica dirigida e neuro-hormonal permitiu a recuperação da função ventricular e a melhoria clínica.

Bridging miocárdico
Atordoamento miocárdico
Insuficiência cardíaca
Texto Completo

Myocardial bridging is a congenital coronary artery abnormality, in which a portion of an epicardial coronary artery takes an intramuscular course,1 and was first described in 1736 by Reyman.2 The tunneled artery segment is compressed during systole and relaxes during diastole. The reported prevalence varies between 0.5% and 16% when assessed by coronary angiography, but in some autopsy series is as high as 80%.3

Nevertheless, despite its high prevalence, most patients are asymptomatic. However, the condition can manifest clinically as myocardial ischemia, acute coronary syndromes, coronary spasms, arrhythmias, left ventricular dysfunction and myocardial stunning, syncope or even sudden death.4

To date, there are only two cases in the literature that describe myocardial stunning caused by myocardial bridging, both related to the left anterior descending (LAD) artery.5,6

Myocardial bridges are most commonly located in the mid LAD artery.7 To date, there is only one published case of myocardial bridging involving three major coronary arteries.8

The development of new imaging techniques has improved the identification and functional evaluation of myocardial bridges, making it possible to link clinical presentation to systolic compression and hence commence therapy.9

Our aim was to present an extremely rare case of myocardial stunning, occurring in the context of myocardial bridging, involving three coronary arteries. Here, we highlight the significance of determining the cause behind myocardial dysfunction in order to select the most suitable therapy, as well as the importance of different imaging techniques to reach a diagnosis.

Case report

The authors describe the case of a 36-year-old female teacher, diagnosed with dilated cardiomyopathy of unknown etiology established at 5 months of age, following growth retardation and the detection of a cardiac murmur. The patient was monitored by a congenital heart disease clinic up until adulthood and medicated with digoxin from 6 to 16 years of age. She was discharged from follow-up in 2007 in New York Heart Association (NYHA) class I and with an echocardiography only showing a mildly dilated left ventricle and preserved left ventricular ejection fraction (54% Simpson's biplane method).

She had no known cardiovascular risk factors, toxic habits or relevant family history, including heart disease at a young age or sudden death. She had an uneventful pregnancy at 28 years of age and has only ever been medicated with the contraceptive pill.

The patient presented to the Emergency Room of another hospital with symptoms of exertional dyspnea, palpitations and lower limb edema lasting one week. She reported that she had recently been experiencing high levels of stress at work, with high blood pressure values detected two months prior to presentation. As a result, she was started on propranolol, which she discontinued due to hypotension and dizziness.

On admission, the patient's blood pressure was 200/130 mmHg. She was tachycardic (120 bpm), afebrile, eupneic and had normal heart sounds. Expiratory time was slightly increased on lung auscultation and she presented with mild bimalleolar edema.

Electrocardiogram (ECG) revealed atrial tachycardia at 138 bpm, with left axis deviation and flattened T waves in leads I, aVL and V5-V6. A full blood count, coagulation test, renal function test and electrolytes were normal; high sensitivity troponin T and creatine kinase (CK) were normal; and mildly elevated transaminases (alanine transaminase: 75 IU/l and aspartate transaminase: 54 IU/l) and D-dimers were observed. Chest X-ray showed bilateral interstitial infiltrate, which was more pronounced at the lung bases, and an increased cardiothoracic ratio. A transthoracic echocardiogram revealed a non-dilated left ventricle with severe global systolic dysfunction (left ventricular ejection fraction [LVEF] 32%), a non-dilated right ventricle, moderate mitral and tricuspid valve regurgitation and an estimated pulmonary artery systolic pressure (PASP) of 50 mmHg. Two intracavitary masses were also seen and assumed to be thrombi.

The patient underwent a computed tomography pulmonary angiography, which revealed a repletion defect in the left ventricle apex and mild bilateral pleural effusion, with no other abnormalities.

Isosorbide dinitrate infusion was initiated, with good hemodynamic response. Anticoagulation with subcutaneous enoxaparin was also started.

The patient was then transferred to our site in less than 24 hours. During her hospital stay, we saw progressive clinical improvement and were able to initiate and uptitrate neurohormonal therapy with a beta-blocker, angiotensin-converting enzyme inhibitors and spironolactone. Ivabradine was also started to optimize heart rate control. Finally, warfarin was prescribed given the initial evidence of intracavitary thrombi.

The ECG evolved spontaneously within the first 24 hours, with sinus rhythm, a heart rate of 74 bpm and inversion of the T waves in leads aVL and V1-V3 (Figure 1).

Figure 1.

Electrocardiogram: sinus rhythm and inversion of the T waves in leads aVL and V1-V3.


A repeat transthoracic echocardiogram showed a mildly dilated left ventricle, with diffuse hypokinesis (more pronounced at the interventricular septum and all the mid and apical segments of the remaining walls) and a severely reduced ejection fraction (LVEF of 18%). Moreover, an image compatible with a sessile thrombus at the apex and a pedunculated and mobile thrombus attached to the mid segment of the anterior septum were seen. Right ventricular (RV) dimensions were at the upper limit of normal and RV function at the lower limit of normal (fractional area change 34%). Furthermore, moderate mitral and tricuspid valve regurgitation and an estimated PASP of 46 mmHg were detected. The inferior vena cava was not dilated, with a 50% inspiratory collapse.

Laboratory blood tests were notable due to an increased of NT-proBNP value (3553 pg/ml on admission and 285 pg/ml at discharge). The remaining laboratory tests were normal, namely the full blood count; iron metabolism; renal function; electrolytes; C-reactive protein and erythrocyte sedimentation rate; glycated hemoglobin (HbA1c) and lipid profile; serial high-sensitivity T troponin and CK values; thyroid function; autoimmunity study and viral serology for HIV, and hepatitis B and C.

In order to rule out pheochromocytoma, a 24-hour urinary metanephrine assay was performed, with normal values.

Cardiac magnetic resonance (CMR) imaging was performed to better characterize the myocardium and intracardiac masses. It confirmed severe biventricular systolic dysfunction (LVEF of 22% and right ventricular ejection fraction of 32%) and segmental wall-motion abnormalities. There was no evidence of signal hyperintensity suggestive of myocardial edema in T2-weighted images. In the early gadolinium enhancement images, no intracavitary thrombi were identified and, likewise, in the late gadolinium enhancement sequences, no areas of late enhancement were detected (Figure 2).

Figure 2.

Cardiac magnetic resonance: no late enhancement detected in four- (A), two- (B) and three- (C) chamber views in late enhancement study.


Following CMR imaging and during the patient's hospital stay, another transthoracic echocardiography was performed, confirming the disappearance of the left ventricular masses seen previously.

To rule out coronary artery disease (CAD), namely congenital coronary abnormalities, a coronary computed tomography angiography was requested. The latter revealed a calcium score of 0, the absence of atherosclerotic lesions and normal coronary ostia origins, with dominant right circulation. It also demonstrated a very marked intramyocardial route of the mid-distal segments of the LAD, diagonal and second obtuse marginal arteries (Figure 3) and distal segments of the interventricular posterior and postero-lateral arteries (Figure 4).

Figure 3.

Computed tomography angiography: three-dimensional reconstruction of the heart showing coronary tree and bridging of left coronary arteries (panel B and D); curved multiplanar reconstruction showing very marked intramyocardial route of the mid-distal segments of left anterior descending artery (panel A), diagonal (panel C) and second obtuse marginal (panel E). Yellow arrows show intramyocardial coronary segments; white arrows show myocardial bridges.

Figure 4.

Computed tomography angiography: three-dimensional reconstruction of the heart showing coronary tree and bridging of right coronary artery (RCA) (panel B); curved multiplanar reconstruction showing very marked intramyocardial distal segments of interventricular posterior artery (RCA/IVP) (panel A) and postero-lateral artery (RCA/PL) (panel C). Yellow arrows show intramyocardial coronary segments; White arrows show myocardial bridges.


In light of this result, we hypothesized that extensive coronary bridging might be the cause of ventricular dysfunction through myocardial stunning.

The patient was discharged for follow-up at the Heart Failure clinic in NYHA class II, on ramipril 5 mg once daily, carvedilol 25 mg twice daily, spironolactone 25 mg once daily, ivabradine 5 mg twice daily and warfarin.

One month after discharge, she underwent a myocardial perfusion scintigraphy, on optimal medical therapy, which revealed a stress-induced reduction of left ventricular systolic function (from 45% at rest to 39% during peak stress) and mild apical ischemia.

Four months after discharge, she went back to work and was in NYHA class I. Her NT-proBNP level was 199 pg/ml and the transthoracic echocardiography revealed an improvement in biventricular function with her left ventricle global systolic function at the lower limit of normal (biplane LVEF of 53%) and preserved right ventricular function.


The importance of this case stems from its rarity, being the second case described in the literature where bridging affects the three epicardial coronary arteries,8 and the third case of myocardial stunning in a myocardial bridging context.5,6 Moreover, it is the first case in which myocardial stunning occurred in three main coronary territories and sufficient biventricular dysfunction led it to be initially interpreted as a case of dilated cardiomyopathy and to manifest as NYHA class III congestive heart failure.

During the initial etiological investigation of this case, we investigated some of the most common causes of dilated cardiomyopathy among this age group and in patients with no cardiovascular risk factors, namely thyroid dysfunction, myocarditis, hypertension, toxic habits and infectious diseases, among others.

The fact that the patient's history of dilated cardiomyopathy dated back to early childhood did raise the possibility of a congenital cause, including coronary artery abnormalities, but since she was a young woman with no risk factors for CAD, and therefore a low probability for atherosclerosis, we decided to perform a coronary computed tomography angiography. Multislice spiral computed tomography defines bridges as segments surrounded by myocardium and is more helpful in identifying hemodynamically significant myocardial bridging. In invasive angiography, diagnosis depends on the change in diameter between systole and diastole within the bridged coronary segment.10 Although this malformation is present at birth, symptoms do not usually develop before the third decade of life, with the reason for this being unclear.3

In this patient, the coronary artery abnormality detected could be the cause of the myocardial dysfunction observed in infancy, through a myocardial stunning mechanism. Myocardial stunning is defined as prolonged yet reversible post-ischemic ventricular dysfunction, usually without tissue necrosis.11 This occurred in our patient who presented with ventricular dysfunction and serial negative troponin values, with no evidence of inflammation or scarring during CMR imaging, and with subsequent LV function recovery.

The pathophysiological mechanisms that contributed to the ischemic insult in this patient could be both her emotional stress-driven tachycardia and documented hypertension. Some authors have reported that tachycardia plays a major role in precipitating ischemic events in the presence of myocardial bridging5,10 by shortening the diastolic period – increasing the importance of systolic blood flow – and decreasing diastolic filling time and coronary flow reserve.2

In addition to the potential contribution of tachycardia to myocardial stunning in a coronary bridging context, the atrial tachycardia presented by this patient at the time of admission (the duration of which was unknown) may have been solely responsible for biventricular dysfunction – a phenomenon called tachycardiomyopathy. The possible mechanisms for myocardial dysfunction within this pathology are myocardial energy depletion, impaired energy utilization and myocardial ischemia, and it usually reverts after heart rate control.12

We have also considered Takotsubo cardiomyopathy13–15 in the differential diagnosis of our patient due to the pattern of the regional wall motion abnormalities and the presence of emotional stress. However, we did not detect any evidence of the myocardial lesions (edema or troponin elevation) that are usually present in this form of cardiomyopathy. Similarly, it was important for us to rule out pheochromocytoma, which can induce myocardial stunning directly or indirectly as a cause of tachycardia. In this case, urinary metanephrines were negative.

With regard to treatment, the nitrate infusion administered before the bridging diagnosis could potentially explain the initial decline in myocardial function (LVEF of 32% on admission, later estimated as 18%). Nitrates should generally be avoided because they increase the angiographic degree of systolic narrowing and can lead to an exacerbation of symptoms16 due to secondary tachycardia and hypercontractility from reflex sympathetic activation.17

In this patient, biventricular function was almost recovered after neurohormonal therapy. In myocardial bridging, heart rate control – in this case through beta-blocker and ivabradine use – allows a longer diastolic time, with consequent improvement of coronary perfusion. Beta-blockers and non-dihydropyridine calcium channel blockers are recommended as first-line drugs7 because, besides heart rate control, they also decrease myocardial contractility and coronary artery compression. Surgical myotomy, intracoronary stenting and coronary artery bypass graft surgery have been used for refractory symptoms, but the long term outcomes remain uncertain.7

Stress single-photon emission computed tomography can detect reversible myocardial perfusion defects in patients with myocardial bridging. The extent of ischemia is related to the degree of systolic luminal narrowing.3 In the reported patient, myocardial scintigraphy revealed a stress-induced decline in systolic function with mild apical ischemia, supporting the hypothesis that ischemia is behind the ventricular dysfunction.

In conclusion, this is the first reported case of myocardial stunning and severe biventricular dysfunction occurring in the context of three-vessel bridging. It also illustrates the importance of identifying a specific cause and mechanism of ventricular dysfunction in heart failure patients, in order to apply guided therapy and thus improve prognosis; in this case this was achieved through the use of multiple imaging modalities.

Conflicts of interest

The authors have no conflicts of interest to declare.

P. Angelni, J.A. Velasco, S. Flamm.
Coronary anomalies: incidence, pathophysiology and clinical relevance.
Circulation, 105 (2002), pp. 2449-2454
H.C. Reyman.
Disertatio de vasis cordis propriis.
Med Diss Univ Göttingen, (7th Sept 1737), pp. 1-32
J.R. Alegria, J. Herrmann, D.R. Holmes Jr., et al.
Myocardial bridging – review.
Eur Heart J, 26 (2005), pp. 1159-1168
M.T. Corban, O.Y. Hung, P. Eshtehardi, et al.
Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies.
J Am Coll Cardiol, 63 (2014), pp. 2346-2355
J.D. Chambers, J.P. Johns, T.B. Berdnt, et al.
Myocardial stunning resulting from systolic coronary artery compression by myocardial bridging.
Am Heart J, 128 (1994), pp. 1036-1038
N. Marchionni, T. Chechi, M. Falai, et al.
Myocardial stunning associated with a myocardial bridge.
Int J Cardiol, 82 (2002), pp. 65-67
P. Poláček, A. Zechmeister.
The occurrence and significance of myocardial bridges and loops on coronary arteries.
Monograph 36, Opuscola Cardiologica. Acta Facultatis Medicae Universitatis Brunenses, pp. 1-99
M.T. Ağaç, L. Korkmaz, H. Erkan.
Three vessels myocardial bridging causing severe angina.
Turk Kardiyol Dern Ars, 41 (2013), pp. 563
S. Möhlenkamp, W. Hort, J. Ge, et al.
Update on myocardial bridging.
Circulation, 106 (2002), pp. 2616-2622
S.M. Yuan.
Myocardial bridging.
Braz J Cardiovasc Surg, 31 (2016), pp. 60-62
E. Braunwald, R. Kloner.
The stunned myocardium: prolonged, postischemic ventricular dysfunction.
Circulation, 66 (1982), pp. 1146-1149
H.A. Mohamed.
Tachycardia induced cardiomyophaty.
Liban J Med, 2 (2007), pp. 26-29
F. Lemaitre, L. Close, N. Yarol, et al.
Role of myocardial bridging in the apical localization of stress cardiomyopathy.
Acta Cardiol, 61 (2006), pp. 545-550
S. Modi, D. Ramsdale.
Takotsubo, hypertrophic obstructive cardiomyopathy & muscle bridging — separate disease entities or a single condition?.
Int J Cardiol, 147 (2011), pp. 133-134
M. Boktor, I.A. Mansi, S. Troxclair, et al.
Association of myocardial bridge and Takotsubo cardiomyopathy: a case report and literature review.
South Med J, 102 (2009), pp. 957-960
Y. Hongo, H. Tada, K. Ito, et al.
Augmentation of vessel squeezing at coronary myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound.
Am Heart J, 138 (1999), pp. 345-350
M.S. Lee, C.H. Chen.
Myocardial bridging: an up-to-date review.
J Invasive Cardiol, 27 (2015), pp. 521-528
Copyright © 2018. Sociedade Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia
Opções de artigo
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.